Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSSRT 1720 is a sirtuin 1 (SIRT1) activator (EC1.5 = 0.16 µM in a cell-free fluorescence polarization assay).1 It reduces acetylated p53 levels in U2OS cells when used at a concentration of 0.1 µM. Oral administration of SRT 1720 (100 mg/kg) reduces fed blood glucose levels, improves insulin sensitivity, and increases mitochondrial capacity in a diet-induced obese (DIO) mouse model of diabetes. It also improves liver, adipose tissue, and skeletal muscle insulin sensitivity in Zucker fa/fa genetically obese rats. SRT 1720 (25 mg/kg) decreases synovitis and delays the progression of surgically induced osteoarthritis in mice.2
WARNING This product is not for human or veterinary use.
1. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450(7170), 712-716 (2007).
2. Intraperitoneal injection of the SIRT1 activator SRT1720 attenuates the progression of experimental osteoarthritis in mice. Bone Joint Res. 7(3), 252-262 (2018).